UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Neonatal lupus: Management and outcomes

Author
Jill P Buyon, MD
Section Editors
Thomas JA Lehman, MD
John K Triedman, MD
Joseph A Garcia-Prats, MD
Deputy Editor
Elizabeth TePas, MD, MS

INTRODUCTION

Neonatal lupus (NL) is an autoimmune disease that is passively transferred from the mother to the fetus. The major manifestations are cardiac and cutaneous findings. The most serious complication of NL is complete heart block (approximately 20 percent have an associated cardiomyopathy at the initial diagnosis or develop it later [1,2]). In this topic review, the cardiac manifestations of NL are referred to as cardiac-NL and can include any degree of block (referred to as congenital heart block [CHB]) that may or may not be accompanied by extranodal disease such as valvular abnormalities, endocardial fibroelastosis, and/or dilated cardiomyopathy. Occasionally, those manifestations may occur in the absence of heart block.

This discussion emphasizes issues related to the treatment and potential prevention of NL. Testing for candidate antibodies is important prior to initiating therapy for a presumed case of cardiac-NL because there are cases of heart block not associated with anti-Ro/SSA (Sjögren syndrome type A antigen) or La/SSB (Sjögren syndrome type B antigen), and, thus, the management may be different. The specific indications for cardiac pacing in infants with congenital complete heart block are discussed separately. (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Screening and surveillance' and "Congenital third degree (complete) atrioventricular block".)

The epidemiology, pathogenesis, clinical manifestations, diagnosis, screening, and surveillance of NL are discussed in greater detail separately. Pregnancy in women with systemic lupus erythematosus (SLE) and diagnosis and management of fetal arrhythmias are also reviewed elsewhere. (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis" and "Pregnancy in women with systemic lupus erythematosus" and "Overview of the general approach to diagnosis and treatment of fetal arrhythmias".)

IN UTERO MANAGEMENT

Complete heart block, once identified, is irreversible despite all therapies attempted to date, including glucocorticoids, pheresis, intravenous immune globulin (IVIG), and hydroxychloroquine [2-5]. Second-degree heart block may be reversible, but it also may progress to complete heart block despite therapy [4-7]. The clinical relevance of first-degree heart block is unclear since progression from first-degree block (defined as a PR interval longer than 150 msec) to more advanced heart block in untreated fetuses has not been well documented but can occur.

Efficacy and side effects of fluorinated glucocorticoids — Published data are limited and discordant regarding the efficacy of fluorinated glucocorticoids in reducing mortality in cardiac-NL. Dexamethasone and betamethasone, which are not inactivated by placental 11-beta dehydrogenase, may ameliorate pleuropericardial effusions or hydrops, and there are reports of improved outcomes [4,8-10]. However, there are risks of glucocorticoid therapy to both the mother (eg, infection, hypertension, avascular necrosis, insulin resistance, and gestational diabetes) and the infant (eg, oligohydramnios, growth restriction, and the still undetermined potential effect upon neurocognitive development) [11]. The use of fluorinated glucocorticoids for each degree of heart block is discussed in the sections below. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Glucocorticoids' and 'First-degree heart block' below and 'Second-degree heart block' below and 'Third-degree heart block' below.)

             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: May 23, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.
  2. Izmirly PM, Saxena A, Sahl SK, et al. Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 2016; 75:1161.
  3. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5:139.
  4. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999; 42:2335.
  5. Friedman DM, Kim MY, Copel JA, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103:1102.
  6. Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.
  7. Yamada H, Kato EH, Ebina Y, et al. Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature. Am J Reprod Immunol 1999; 42:226.
  8. Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.
  9. Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110:1542.
  10. Hutter D, Silverman ED, Jaeggi ET. The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: a review. Scand J Immunol 2010; 72:235.
  11. Breur JM, Visser GH, Kruize AA, et al. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004; 24:467.
  12. Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485.
  13. Jaeggi ET, Silverman ED, Laskin C, et al. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SSA and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol 2011; 57:1487.
  14. Rein AJ, Mevorach D, Perles Z, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009; 119:1867.
  15. Mevorach D, Elchalal U, Rein AJ. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. Curr Opin Rheumatol 2009; 21:478.
  16. Sonesson SE, Salomonsson S, Jacobsson LA, et al. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50:1253.
  17. Krishnan AN, Sable CA, Donofrio MT. Spectrum of fetal echocardiographic findings in fetuses of women with clinical or serological evidence of systemic lupus erythematosus. J Matern Fetal Neonatal 2008; 21:778.
  18. Gardiner HM, Belmar C, Pasquini L, et al. Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies. Heart 2007; 93:1454.
  19. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.
  20. Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544.
  21. Levesque K, Morel N, Maltret A, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015; 14:1154.
  22. Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124:1919.
  23. McCurdy CM, Reed KL. Fetal Arrhythmias. In: Doppler Ultrasound in Obstetrics and Gynecology, Copel JA, Reed KL (Eds), Raven Press, New York 1995. p.253.
  24. Lopes LM, Tavares GM, Damiano AP, et al. Perinatal outcome of fetal atrioventricular block: one-hundred-sixteen cases from a single institution. Circulation 2008; 118:1268.
  25. Groves AM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995; 92:3394.
  26. Trucco SM, Jaeggi E, Cuneo B, et al. Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy. J Am Coll Cardiol 2011; 57:715.
  27. Guettrot-Imbert G, Cohen L, Fermont L, et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies. J Rheumatol 2011; 38:378.
  28. Bergman G, Eliasson H, Mohlkert LA, et al. Progression to first-degree heart block in preschool children exposed in utero to maternal anti-SSA/Ro52 autoantibodies. Acta Paediatr 2012; 101:488.
  29. Klauninger R, Skog A, Horvath L, et al. Serologic follow-up of children born to mothers with Ro/SSA autoantibodies. Lupus 2009; 18:792.
  30. Askanase AD, Miranda-Carus ME, Tang X, et al. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum 2002; 46:269.
  31. Bergman G, Skog A, Tingström J, et al. Late development of complete atrioventricular block may be immune mediated and congenital in origin. Acta Paediatr 2014; 103:275.
  32. Costedoat-Chalumeau N, Amoura Z, Le Thi Hong D, et al. Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 2003; 62:1010.
  33. Martin V, Lee LA, Askanase AD, et al. Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum 2002; 46:2377.
  34. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69:1827.
  35. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.
  36. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62:1138.
  37. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62:1147.